---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-113631"
form_type: "8-K"
ticker: "CLSDQ"
cik: "0001539029"
company_name: "Clearside Biomedical, Inc."
filed_at: "2024-10-09T23:59:59+00:00"
generated_at: "2026-05-30T17:18:16.904910+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Clearside reports positive ODYSSEY Phase 2b results for CLS-AX in wet AMD; all endpoints met

## Summary
- ODYSSEY Phase 2b trial of suprachoroidal CLS-AX achieved primary and secondary outcomes; stable BCVA and CSRT through 36 weeks.
- 67% of CLS-AX participants required no additional treatment up to 6 months; 90% up to 4 months, 81% up to 5 months.
- Treatment burden reduced by ~84% compared to average monthly injections prior to screening.
- No ocular or treatment-related SAEs; no endophthalmitis, no retinal vasculitis; well-tolerated safety profile.
- Company plans to advance CLS-AX into Phase 3 development.

## SEC filing metadata
- accession: 0000950170-24-113631
- form_type: 8-K
- ticker: CLSDQ
- cik: 0001539029
- company_name: Clearside Biomedical, Inc.
- filed_at: 2024-10-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1539029/000095017024113631/0000950170-24-113631-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1539029/000095017024113631/clsd-20241009.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-113631
- JSON: https://secwatch.observer/filing/0000950170-24-113631.json
- Plain text: https://secwatch.observer/filing/0000950170-24-113631.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.